Literature DB >> 27704734

Are Community-Based Hospitals Safe from Carbapenem-Resistant Enterobacteriaceae in Korea?

Chang Seop Lee1,2.   

Abstract

Entities:  

Year:  2016        PMID: 27704734      PMCID: PMC5048010          DOI: 10.3947/ic.2016.48.3.246

Source DB:  PubMed          Journal:  Infect Chemother        ISSN: 1598-8112


× No keyword cloud information.
Carbepenems are used with increasing frequency to treat multidrug-resistant isolates, especially strains producing extended-spectrum β-lactamases [12]. Resistance to carbapenems has been uncommon among Enterobacteriaceae. However, the emergence of β-lactamases with direct carbapenem-hydrolyzing activity has contributed to an increased prevalence of carbapenem-resistant Enterobacteriaceae (CRE) [3]. CRE are particularly problematic given the high mortality associated with infections caused by CRE, and the potential for widespread transmission of carbapenem resistance via mobile genetic elements [34]. We should recall 2 outbreaks in New York City [5]. At hospital A, 2 patients with carbapenem-resistant Klebsiella pneumoniae (CRKP) were identified. During the next 6 months, a total of 30 additional patients were identified as having CRKP. Thirty of 32 isolates were considered to be acquired nosocomially, with median length of hospital stay before a positive culture result of 18.5 days. At hospital B, an initial case of CRKP was recognized, followed by 2 more cases within 2 months. In the ensuing 3 months, another 24 cases were identified. All isolates were considered to be acquired nosocomially. We assume that horizontal transmission of carbapenem-resistant organisms occurred at these 2 hospitals. The emergence of carbapenem-resistant Gram-negative bacteria has been increasingly reported, especially Pseudomonas aeruginosa, Acinetobacter baumannii, and Enterobacter spp. in Korea [6]. Among Gram-negative bacteria, the proportion of CRE has been very low, compared with that of P. aeruginosa and A. baumannii [16]. However, the trend is increasing [6]. Lee et al. [7] investigated the prevalence and risk factors of CRE in a single community-based hospital in Korea. Until now, most research on carbapenem-resistant Gram-negative bacteria including CRE was performed in tertiary acute care hospitals in Korea. However, Lee et al. conducted their study at a mid-sized community-based hospital, including not only the intensive care unit but also the general wards. Many patients had been transferred from long-term care facilities (LTCFs). In this study, a total of 41 (1.6%) CRE isolates were identified, including 13 of Enterobacter aerogenes, 8 of K. pneumoniae, 5 of Enterobacter cloacae, and 15 others. They reported that risk factors for CRE included vascular catheters, high comorbidity score, and regular visits to the outpatient clinic. CRE carriage has been described in a number of investigations involving those in LTCFs. In one study, 9 carbapenem-resistant Escherichia coli isolates harboring K. pneumoniae carbapenemase were identified in patients residing in 7 different LTCFs [8]. In other reports, about 60% of patients with CRKP were admitted from post-acute care facilities [9]. These results suggest that LTCFs can be important reservoirs for the transmission and dissemination of these organisms. Well-known risk factors for CRE acquisition or infection include recent organ or stem-cell transplantation, mechanical ventilation, exposure to antimicrobials, and longer length of stay [310]. In one study, the risk factors for CRKP included previous use of carbapenems, cephalosporins, and fluoroquinolones [410]. In other reports, poor functional status and intensive care unit stay were risk factors for CRKP [4]. In conclusion, CRE is threatening not only tertiary acute care hospitals but also mid-sized community hospitals in Korea. LTCFs are possible reservoirs for the threat of CRE. Because of high mortality rates and the possibility of outbreaks, each hospital must detect CRE as soon as possible and aggressively perform infection control to perfection. For CRE prevention, we recommend active surveillance in high-risk groups admitted to the hospital, whether in a tertiary acute care or mid-sized community-based hospital. In addition, we should apply antimicrobial stewardship to decrease carbapenem consumption in hospitals and to minimize device usage in clinical settings. We absolutely should perform appropriate infection control procedures, including use of personal protective equipment and good hand hygiene following exposure to patient environments.
  10 in total

Review 1.  Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention.

Authors:  Neil Gupta; Brandi M Limbago; Jean B Patel; Alexander J Kallen
Journal:  Clin Infect Dis       Date:  2011-07-01       Impact factor: 9.079

2.  Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium.

Authors:  Simona Bratu; David Landman; Robin Haag; Rose Recco; Antonella Eramo; Maqsood Alam; John Quale
Journal:  Arch Intern Med       Date:  2005-06-27

3.  Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination.

Authors:  Federico Perez; Andrea Endimiani; Amy J Ray; Brooke K Decker; Christopher J Wallace; Kristine M Hujer; David J Ecker; Mark D Adams; Philip Toltzis; Michael J Dul; Anne Windau; Saralee Bajaksouzian; Michael R Jacobs; Robert A Salata; Robert A Bonomo
Journal:  J Antimicrob Chemother       Date:  2010-05-31       Impact factor: 5.790

4.  Four Year Trend of Carbapenem-Resistance in Newly Opened ICUs of a University-Affiliated Hospital of South Korea.

Authors:  Bo Min Kim; Eun Ju Jeon; Ju Young Jang; Jin-Won Chung; Jihoon Park; Jae Chol Choi; Jong Wook Shin; In Won Park; Byoung Whui Choi; Jae Yeol Kim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2012-04-30

5.  Carbapenem-resistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase beta-lactamases associated with long-term care facilities.

Authors:  Carl Urban; Patricia A Bradford; Margareta Tuckman; Sorana Segal-Maurer; Wehbeh Wehbeh; Louise Grenner; Rita Colon-Urban; Noriel Mariano; James J Rahal
Journal:  Clin Infect Dis       Date:  2008-06-01       Impact factor: 9.079

6.  Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies.

Authors:  Gopi Patel; Shirish Huprikar; Stephanie H Factor; Stephen G Jenkins; David P Calfee
Journal:  Infect Control Hosp Epidemiol       Date:  2008-12       Impact factor: 3.254

7.  Continuous increase of the antimicrobial resistance among gram-negative pathogens causing bacteremia: a nationwide surveillance study by the Korean Network for Study on Infectious Diseases (KONSID).

Authors:  Kyungmin Huh; Jungok Kim; Sun Young Cho; Young Eun Ha; Eun-Jeong Joo; Cheol-In Kang; Doo Ryeon Chung; Nam Yong Lee; Jae-Hoon Song; Kyong Ran Peck
Journal:  Diagn Microbiol Infect Dis       Date:  2013-05-28       Impact factor: 2.803

8.  Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality.

Authors:  Mitchell J Schwaber; Shiri Klarfeld-Lidji; Shiri Navon-Venezia; David Schwartz; Azita Leavitt; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2007-12-17       Impact factor: 5.191

9.  Carbapenem-resistant Enterobacteriaceae: Prevalence and Risk Factors in a Single Community-Based Hospital in Korea.

Authors:  Hyo Jin Lee; Jae Ki Choi; Sung Yeon Cho; Si Hyun Kim; Sun Hee Park; Su Mi Choi; Dong Gun Lee; Jung Hyun Choi; Jin Hong Yoo
Journal:  Infect Chemother       Date:  2016-09-08

10.  Trends of Antibiotic Consumption in Korea According to National Reimbursement Data (2008-2012): A Population-Based Epidemiologic Study.

Authors:  Young Kyung Yoon; Gi Chan Park; Hyonggin An; Byung Chul Chun; Jang Wook Sohn; Min Ja Kim
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  10 in total
  1 in total

Review 1.  Urgent need for novel antibiotics in Republic of Korea to combat multidrug-resistant bacteria.

Authors:  Hyo-Jin Lee; Dong-Gun Lee
Journal:  Korean J Intern Med       Date:  2022-02-28       Impact factor: 2.884

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.